{
    "Rank": 948,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03572361",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "V3-MOMMO-01"
                },
                "Organization": {
                    "OrgFullName": "Immunitor LLC",
                    "OrgClass": "INDUSTRY"
                },
                "BriefTitle": "Open Label Immunotherapy Trial for Breast Cancer",
                "OfficialTitle": "Open Label, One-arm, 3-month Study of Once-daily Tablet of V3-MOMMO as Immunotherapy of Breast Cancer",
                "Acronym": "V3-MOMMO"
            },
            "StatusModule": {
                "StatusVerifiedDate": "August 2019",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "July 1, 2018",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "November 30, 2019",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 31, 2019",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "June 16, 2018",
                "StudyFirstSubmitQCDate": "June 26, 2018",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "June 28, 2018",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "August 29, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "August 30, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Immunitor LLC",
                    "LeadSponsorClass": "INDUSTRY"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This Phase II will evaluate a new type of breast cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. Investigators will test new tableted preparation, V3-MOMMO, obtained from hydrolyzed, inactivated blood and tumors of patients with breast cancer. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.",
                "DetailedDescription": "Worldwide, breast cancer is the number one cancer in women. It affects about 12% or 1.7 mln women worldwide. In Mongolia breast cancer is less common, occupies 5-th place by frequency in women, the incidence is 118 per 100,000 or 1,770 cases per year.\n\nMany different types of immunotherapy (especially checkpoint inhibitors) are being tested, but so far the successes have been insignificant, and serious side effects are frequent and unpredictable. This Phase II will evaluate a new type of breast cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. Investigators will test new tableted preparation, V3-MOMMO, obtained from hydrolyzed, inactivated blood and tumor tissues of patients with breast cancer. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and lymph nodes burden after 3 months. Secondary endpoint will be effect on levels of tumor markers (i.e., cancer antigen 15-3 (CA 15-3), cancer antigen 27.29 (CA 27.29), and carcinoembryonic antigen (CEA) on monthly basis compared to baseline."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignInterventionModelDescription": "Single arm, open label Phase II study in volunteers with breast cancer receiving daily dose of one pill of vaccine V3-MOMMO",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)",
                        "DesignMaskingDescription": "No masking"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "20",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "V3-MOMMO",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: V3-MOMMO"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "V3-MOMMO",
                            "InterventionDescription": "Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "V3-MOMMO"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Effect on tumor size",
                            "PrimaryOutcomeDescription": "Changes in tumor size and lymph node burden (if any) compared to baseline",
                            "PrimaryOutcomeTimeFrame": "Monthly for 3 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Effect on level of serum tumor markers compared to baseline",
                            "SecondaryOutcomeDescription": "Commonly measured tumor markers associated with breast cancer, primarily CA 15-3, CA 27.29, and CEA, at baseline and at study termination",
                            "SecondaryOutcomeTimeFrame": "Monthly for three months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nConfirmed diagnosis of breast cancer positive at least for CEA tumor marker at above normal threshold level\n\nExclusion Criteria:\n\nMastectomy",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "GenderBased": "Yes",
                "GenderDescription": "Majority of subjects with breast cancer are females",
                "MinimumAge": "18 Years",
                "MaximumAge": "65 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Galyna Kutsyna, MD, MD/PhD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+97695130306",
                            "CentralContactEMail": "kutsynagalyna@yahoo.com"
                        },
                        {
                            "CentralContactName": "Aldar Bourinbayar, MD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+97695130306",
                            "CentralContactEMail": "marinatarakanovskaya@yahoo.com"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Aldar Bourinbayar, PhD, MD/PhD",
                            "OverallOfficialAffiliation": "Immunitor LLC",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Immunitor LLC",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Ulaanbaatar",
                            "LocationCountry": "Mongolia",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Aldar Bourinbaiar, MD",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "97695130306",
                                        "LocationContactEMail": "aldar@immunitor.com"
                                    },
                                    {
                                        "LocationContactName": "Marina Tarakanovskaya, MD",
                                        "LocationContactRole": "Contact",
                                        "LocationContactEMail": "marinatarakanovskaya@yahoo.com"
                                    },
                                    {
                                        "LocationContactName": "Galyna Kutsyna, MD",
                                        "LocationContactRole": "Principal Investigator"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "28443252",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, Borisova V, Bain AI, Jirathitikal V, Bourinbaiar AS. Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcinoma. 2017 Apr 12;4:59-69. doi: 10.2147/JHC.S122507. eCollection 2017."
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2854",
                            "InterventionBrowseLeafName": "Immunomodulating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}